Williams PhD, Marshall V, Cox, Brandon, Lafuse PhD, William P et al. · Clinical therapeutics · 2019 · DOI
Quick Summary
This study explores whether a protein from the Epstein-Barr virus (EBV) may trigger brain inflammation in ME/CFS patients. Researchers found that this viral protein can change how brain cells function and alter important chemical pathways involved in energy, mood, and pain processing. The findings suggest that in some ME/CFS patients, this viral protein might contribute to fatigue, pain, and thinking difficulties.
Why It Matters
This study provides a potential biological mechanism explaining neuroinflammation in a subset of ME/CFS patients and identifies EBV dUTPase as a candidate therapeutic target. Understanding the specific molecular pathways disrupted could lead to targeted treatments addressing fatigue, pain, and cognitive symptoms. The finding that 30-53% of ME/CFS patients have antibodies against multiple viral dUTPases suggests this mechanism may be clinically relevant for patient stratification.
Observed Findings
30.91%-52.7% of ME/CFS patients produced antibodies against multiple herpesvirus-encoded dUTPases and/or human dUTPase
EBV dUTPase altered expression of 12 of 15 genes related to blood-brain barrier function in cultured human brain cells
EBV dUTPase changed expression of 34 of 84 genes in mouse brains involved in dopamine, serotonin, tryptophan, GABA, and glutamate pathways
EBV dUTPase induced anxiety and sickness behaviors in female mice in prior studies
A small subset of ME/CFS patients had prolonged elevated neutralizing antibodies against EBV dUTPase that inversely correlated with symptom severity
Inferred Conclusions
EBV dUTPase protein may initiate neuroinflammation in a subset of ME/CFS patients by disrupting blood-brain barrier integrity
EBV dUTPase alters neurotransmitter systems (dopamine, serotonin, GABA, glutamate) and tryptophan metabolism relevant to fatigue, pain, and cognitive dysfunction
EBV dUTPase could be a targetable factor contributing to symptoms in patients with elevated dUTPase-specific antibodies
The elevated antibody prevalence suggests EBV dUTPase-mediated pathology may account for ME/CFS symptoms in approximately one-third to one-half of patients
Remaining Questions
What This Study Does Not Prove
This study does not prove that EBV dUTPase causes ME/CFS or that it is the primary mechanism in all patients—it demonstrates association and in vitro/animal effects only. The elevated antibodies in patient serum are correlational findings and do not establish active viral protein as the causative agent. The relevance of mouse models to human ME/CFS pathophysiology remains to be validated in human CNS tissue studies.
Does active EBV dUTPase protein circulate in ME/CFS patient serum and cross the blood-brain barrier to exert these effects, or is antibody presence a marker of past exposure?
Do patients with elevated dUTPase antibodies show different clinical phenotypes or treatment responses compared to seronegative ME/CFS patients?
Can EBV dUTPase-neutralizing antibodies or other targeted interventions reverse the neuroinflammatory gene expression changes and improve symptoms?
What percentage of ME/CFS patients have active viral replication producing dUTPase versus antibody responses to past infection, and how does this correlate with disease severity?